This is a snippet of the transcript, sign up to read more.
If you take a step back and try to understand what is being presented to the investor base, there are three things. One is that during Covid, an issue arose where parts used for the electronic side of the business was being substituted by suppliers. Given the high-performance requirements of these particular freezers and the energy driven by the system, these parts were prematurely failing in some cases. It didn't happen in all cases, but it was hard to predict. Several different small components on the electronic board would fail, which became the first issue. We characterized it and provided BioLife with some insight into what was happening during the time of the acquisition.
This is a snippet of the transcript, sign up to read more.
However, the executive management team, excluding probably the quality lead for the business, was not designed to manage the complexities of a hardware business. They treated these assets as separate standalone entities with little integration. They were managing the business like a holding company, where each of the respective businesses were standalone and measured as such. As the Chief Operating Officer, I had a few opportunities to help them examine the supply chain. There were a few leverage points, but not many.
This is a snippet of the transcript, sign up to read more.
In the biologics space, most materials are stored between -20 and -80 degrees Celsius. For instance, blood is typically stored at -80, while other materials, like saliva, are stored at -20. There are other biologic materials that fall within that spectrum. What attracted me to this technology was not only its ability to accommodate this range in a single device but also the potential for other applications. However, when Covid hit and demand increased, we had to focus on the operational challenges of scaling up to support the business.
This is a snippet of the transcript, sign up to read more.
This document may not be reproduced, distributed, or transmitted in any form or by any means including resale of any part, unauthorised distribution to a third party or other electronic methods, without the prior written permission of IP 1 Ltd.
IP 1 Ltd, trading as In Practise (herein referred to as "IP") is a company registered in England and Wales and is not a registered investment advisor or broker-dealer, and is not licensed nor qualified to provide investment advice.
In Practise reserves all copyright, intellectual and other property rights in the Content. The information published in this transcript (“Content”) is for information purposes only and should not be used as the sole basis for making any investment decision. Information provided by IP is to be used as an educational tool and nothing in this Content shall be construed as an offer, recommendation or solicitation regarding any financial product, service or management of investments or securities. The views of the executive expressed in the Content are those of the expert and they are not endorsed by, nor do they represent the opinion of In Practise. In Practise makes no representations and accepts no liability for the Content or for any errors, omissions, or inaccuracies will in no way be held liable for any potential or actual violations of laws, including without limitation any securities laws, based on Information sent to you by In Practise.
© 2024 IP 1 Ltd. All rights reserved.
Subscribe to access hundreds of interviews and primary research